BCHE and Alzheimer disease: As cholinergic and adrenergic signaling is dysregulated owing to substantially reduced ACh synthesis in patients with AD, cholinesterase (ChE) inhibitors are prescribed as the first-line agents for AD management to increase ACh concentration by inhibiting hydrolyzing enzymes, such as acetylcholinesterase (AChE) and butyrylcholinesterase.